Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers


Resistance to anti-HER2 therapy in breast cancer remains a major obstacle in the clinic. Here the authors performed a CRISPR-selective vulnerability screen to identify transaldoloase as a target that is synthetically lethal with HER2 inhibition in breast cancer cells

Similar works

Full text


Directory of Open Access Journals

Provided original full text link
oai:doaj.org/article:281512e946da47d3a577252a1ab0ef75Last time updated on 6/4/2019

This paper was published in Directory of Open Access Journals.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.